CoChat

KTE-X19 anti-CD19 CAR T-cell therapy in adult relapsed/refractory acute lymphoblastic leukemia: ZUMA-3 phase 1 results

Open access
Shah, Bijal D., Bishop, Michael R., Oluwole, Olalekan O., Logan, Aaron C., Baer, Maria R., Donnellan, William B., O’Dwyer, Kristen M., Holmes, Houston, Arellano, Martha L., Ghobadi, Armin, Pagel, John M., Lin, Yi, Cassaday, Ryan D., Park, Jae H., Abedi, Mehrdad, Castro, Januario E., DeAngelo, Daniel J., Malone, Adriana K., Mawad, Raya, Schiller, Gary J., Rossi, John M., Bot, Adrian, Shen, Tong, Goyal, Lovely, Jain, Rajul K., Vezan, Remus, Wierda, William G. · 2021 · Blood
Cited by 201

The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.

Abstract

ZUMA-3 is a phase 1/2 study evaluating KTE-X19, an autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy, in adult relapsed/refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL). We report the phase 1 results. After fludarabine-cyclophosphamide lymphodepletion, patients received a single infusion of KTE-X19 at 2 × 106, 1 × 106, or 0.5 × 106 cells per kg. The rate of dose-limiting toxicities (DLTs) within 28 days after KTE-X19 infusion was the primary end point. KTE-X19 was manufactured for 54 enrolled patients and administered to 45 (median age, 46 years; range, 18-77 years). No DLTs occurred in the DLT-evaluable cohort. Grade ≥3 cytokine release syndrome (CRS) and neurologic events (NEs) occurred in 31% and 38% of patients, respectively. To optimize the risk-benefit ratio, revised adverse event (AE) management for CRS and NEs (earlier steroid use for NEs and tocilizumab only for CRS) was evaluated at 1 × 106 cells per kg KTE-X19. In the 9 patients treated under revised AE management, 33% had grade 3 CRS and 11% had grade 3 NEs, with no grade 4 or 5 NEs. The overall complete remission rate correlated with CAR T-cell expansion and was 83% in patients treated with 1 × 106 cells per kg and 69% in all patients. Minimal residual disease was undetectable in all responding patients. At a median follow-up of 22.1 months (range, 7.1-36.1 months), the median duration of remission was 17.6 months (95% confidence interval [CI], 5.8-17.6 months) in patients treated with 1 × 106 cells per kg and 14.5 months (95% CI, 5.8-18.1 months) in all patients. KTE-X19 treatment provided a high response rate and tolerable safety in adults with R/R B-ALL. Phase 2 is ongoing at 1 × 106 cells per kg with revised AE management. This trial is registered at www.clinicaltrials.gov as #NCT02614066.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1182/blood.2020009098

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 7 references

Cited by

See all 201

Metadata

Authors
Shah, B. D., Bishop, M. R., Oluwole, O. O., Logan, A. C., Baer, M. R., Donnellan, W. B., O’Dwyer, K. M., Holmes, H., Arellano, M. L., Ghobadi, A., Pagel, J. M., Lin, Y., Cassaday, R. D., Park, J. H., Abedi, M., Castro, J. E., DeAngelo, D. J., Malone, A. K., Mawad, R., Schiller, G. J., Rossi, J. M., Bot, A., Shen, T., Goyal, L., Jain, R. K., Vezan, R., & Wierda, W. G.
Venue
Blood
Published
2021-04-07
Volume
138
Issue
1
Pages
11-22
ISSN
  • 0006-4971 (ISSN-L)
  • 1528-0020
OpenAlex
W3146763078
Cited by
201
References
7
FWCI
11.99
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: KTE-X19 anti-CD19 CAR T-cell therapy in adult relapsed/refractory acute lymphoblastic leukemia: ZUMA-3 phase 1 results. https://app.cochat.ai/papers/10.1182/blood.2020009098
The paper
Shah, B. D., Bishop, M. R., Oluwole, O. O., Logan, A. C., Baer, M. R., Donnellan, W. B., O’Dwyer, K. M., Holmes, H., Arellano, M. L., Ghobadi, A., Pagel, J. M., Lin, Y., Cassaday, R. D., Park, J. H., Abedi, M., Castro, J. E., DeAngelo, D. J., Malone, A. K., Mawad, R., . . . Wierda, W. G. (2021). KTE-X19 anti-CD19 CAR T-cell therapy in adult relapsed/refractory acute lymphoblastic leukemia: ZUMA-3 phase 1 results. Blood. https://doi.org/10.1182/blood.2020009098

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.